Portal de Periódicos da CAPES

RISPERIDONE IN PRADER-WILLI SYNDROME

2000; Elsevier BV; Volume: 39; Issue: 5 Linguagem: Inglês

10.1097/00004583-200005000-00004

1527-5418

Rimona Durst, Karny Rubin-Jabotinsky, Sergey Raskin, Grégory Katz, Josef Zislin,

Adolescent and Pediatric Healthcare

We would like to report our promising results with risperidone in the treatment of patients suffering from Prader-Willi syndrome (PWS). First described in the German literature in 1956, PWS is defined as a genetic disorder that can appear in a sporadic form. Typical behavioral symptoms of PWS include stubbornness, impulsivity, aggressiveness, explosivity, temper tantrums, self-mutilation, poor peer relationships, obsessive food-seeking, and hyperphagia. The behavioral manifestations of PWS, which are severe in nature, become prominent in late childhood and adolescence and may lead to morbid obesity accompanied by life-threatening cardiac-respiratory complications.